{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ZILRETTA&page=9",
    "query": {
      "intervention": "ZILRETTA",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 390,
    "total_pages": 39,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ZILRETTA&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ZILRETTA&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-08T00:56:44.362Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00791934",
      "title": "Clinical Study of Safety and Efficacy for the Relieva Stratus With Elution of Triamcinolone Acetonide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sinusitis"
      ],
      "interventions": [
        {
          "name": "Stratus Microflow Ethmoid Spacer",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Integra LifeSciences Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2008-08",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-11-08T00:56:44.362Z",
      "location_count": 1,
      "location_summary": "Burlington, Massachusetts",
      "locations": [
        {
          "city": "Burlington",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00791934"
    },
    {
      "nct_id": "NCT02454088",
      "title": "A Single-Center Investigator-Initiated Evaluator-Bilateral-Comparison Pilot Study of Injectable Calcium Hydroxylapatite With and Without Triamcinolone Acetate for the Treatment of Volume Loss to Dorsum Areas of the Hands",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Volume Loss to Dorsum of Hands"
      ],
      "interventions": [
        {
          "name": "Calcium Hydroxylapatite and Triamcinolone acetate",
          "type": "OTHER"
        },
        {
          "name": "Calcium Hydroxylapatite and Placebo",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "Goldman, Butterwick, Fitzpatrick and Groff",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2015-05",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2017-03-01",
      "last_synced_at": "2026-11-08T00:56:44.362Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02454088"
    },
    {
      "nct_id": "NCT00312208",
      "title": "Docetaxel in Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel,doxorubicin, cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 70 Years · Female only"
      },
      "enrollment_count": 3299,
      "start_date": "2001-11",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2013-12-30",
      "last_synced_at": "2026-11-08T00:56:44.362Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00312208"
    },
    {
      "nct_id": "NCT03605927",
      "title": "CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Graft-versus-host-disease",
        "GVHD",
        "GVHD, Acute"
      ],
      "interventions": [
        {
          "name": "BMS-986004",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2019-02-15",
      "completion_date": "2023-07-25",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-11-08T00:56:44.362Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Tampa, Florida • Columbus, Ohio",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03605927"
    },
    {
      "nct_id": "NCT03382262",
      "title": "Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis of the Shoulder",
        "Osteoarthritis of the Hip"
      ],
      "interventions": [
        {
          "name": "FX006 32 mg",
          "type": "DRUG"
        },
        {
          "name": "TAcs 40 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pacira Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2017-12-18",
      "completion_date": "2018-10-09",
      "has_results": true,
      "last_update_posted_date": "2024-01-24",
      "last_synced_at": "2026-11-08T00:56:44.362Z",
      "location_count": 6,
      "location_summary": "El Cajon, California • La Mesa, California • San Diego, California + 3 more",
      "locations": [
        {
          "city": "El Cajon",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03382262"
    },
    {
      "nct_id": "NCT03627741",
      "title": "A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Fibromatosis"
      ],
      "interventions": [
        {
          "name": "Triamcinolone Acetonide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 10,
      "start_date": "2018-06-07",
      "completion_date": "2022-07-05",
      "has_results": false,
      "last_update_posted_date": "2022-08-25",
      "last_synced_at": "2026-11-08T00:56:44.362Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03627741"
    },
    {
      "nct_id": "NCT00846690",
      "title": "Comparative Efficacy of 20% Benzocaine Versus TAC Alternate Gel",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dental Pain",
        "Postoperative Pain"
      ],
      "interventions": [
        {
          "name": "benzocaine",
          "type": "DRUG"
        },
        {
          "name": "TAC alternate gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 20,
      "start_date": "2009-01",
      "completion_date": "2009-05",
      "has_results": false,
      "last_update_posted_date": "2009-02-19",
      "last_synced_at": "2026-11-08T00:56:44.362Z",
      "location_count": 1,
      "location_summary": "6655 Travis Suite 460, Texas",
      "locations": [
        {
          "city": "6655 Travis Suite 460",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00846690"
    },
    {
      "nct_id": "NCT01467505",
      "title": "An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Telaprevir",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Interferon Alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Immunosuppressant Regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 61,
      "start_date": "2012-02",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2015-06-18",
      "last_synced_at": "2026-11-08T00:56:44.362Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01467505"
    },
    {
      "nct_id": "NCT06731504",
      "title": "HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hematologic Malignancy"
      ],
      "interventions": [
        {
          "name": "Abatacept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2025-11-12",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-11-06",
      "last_synced_at": "2026-11-08T00:56:44.362Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06731504"
    },
    {
      "nct_id": "NCT07832552",
      "title": "A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Postoperative Ocular Inflammation",
        "Postoperative Ocular Pain"
      ],
      "interventions": [
        {
          "name": "Sham (No Treatment)",
          "type": "PROCEDURE"
        },
        {
          "name": "TRIESENCE (triamcinolone acetonide injectable suspension)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Harrow Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2026-05-25",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-11-08T00:56:44.362Z",
      "location_count": 1,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07832552"
    }
  ]
}